Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1415-1422

  Gamez, Idoia ^a   Ryan, Robert P ^a   Reid, Lakesha D ^b   Routt, Sheri M ^b   Hollister, Beth A ^b  

^a Celtic Pharmaceutical Development Services America Inc   (United States)

^b Piedmont Research Center   (United States)

Author keywords

Antitumor; Avastin ; Bevacizumab; Corticorelin acetate; Corticotropin releasing factor; Xerecept

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CORTICORELIN ACETATE; UNCLASSIFIED DRUG; XERECEPT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; BREAST CARCINOMA; COLON CARCINOMA; CONTROLLED STUDY; CORNEAL MICROPOCKET ASSAY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLONIC NEOPLASMS; CORTICOTROPIN-RELEASING HORMONE; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS;

EID: 79959582372     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1437-3     Document Type: Article

References (30)

1. Stummer W (2007) Mechanisms of tumor-related brain edema. Neurosurg Focus 22:E8
2. Lee SW, Kim WJ, Park JA, Choi YK, Kwon YW, Kim KW (2006) Blood-brain barrier interfaces and brain tumors. Arch Pharm Res 29:265-275 (Pubitemid 43685278)
3. Tjuvajev J, Uehara H, Desai R, Beattie B, Matei I, Zhou Y, Kreek MJ, Koutcher J, Blasberg R (1996) Corticotropin-releasing factor decreases vasogenic edema. Cancer Res 56:1352-1360 (Pubitemid 26080979)
4. Kaal EC, Vecht CJ (2004) The management of brain edema in brain tumors. Curr Opin Oncol 16:593-600 (Pubitemid 39482980)
5. Grammatopoulos DK, Chrousos GP (2002) Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13:436-444 (Pubitemid 36733938)
6. Hillhouse EW, Grammatopoulos OK (2006) The molecular mechanisms underlying the regulation of the biological activity of corticotropin releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27:260-286
7. Reubi JC, Waser W, Vale W, Rivier J (2003) Expression of CRF1 and CRF2 receptors in human cancers. J Clin Endocrinol Metab 88:3312-3320 (Pubitemid 36877510)
8. Bale TL, Giordano FJ, Vale WW (2003) A new role for corticotrophin- releasing factor receptor-2: suppression of vascularization. Trends Cardiovasc Med 13:68-71 (Pubitemid 36175530)
9. Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G, Li S (2008) Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26:359-368 (Pubitemid 351601386)
10. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ (1996) A model of angiogenesis in the mouse cornea. Invest Ophtalmol Vis Sci 37:1625-1632 (Pubitemid 26271414)
11. Recht LD, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milsted R, O'Connor PC, Ryan RP, Wong ET (2009) A placebo-controlled study investigating the dexamethasone-sparing effects of corticorelin acetate in patients with primary or metastatic brain tumors and peritumoral edema. J Clin Oncol 27:abstr 2078
12. Mechtler L, Wong ET, Hormigo A, Pannullo S, Hines V, Milsted R, O'Connor PO, Ryan RP, Recht L (2009) A long-term openlabel extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors. J Clin Oncol 27:abstr 2079
13. Shapiro WR, Mechtler L, Cher L, Wheeler H, Hines V, Milsted R, O'Connor PC, Ryan RP, L. Recht L (2009) A randomized, double-blind study comparing corticorelin acetate with dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptoms of peritumoral brain edema. J Clin Oncol 27:abstr 2080
14. Moliterno JA, Henry E, Pannullo SC (2009) Corticorelin acetate injections for the treatment of peritumoral brain edema. Expert Opin Investig Drugs 18:1413-1419
15. Ryan R, Moroz M, Berestein T, Evans-Freke S, Gamez I, Hines V, and Blasberg R (2009) Corticorelin acetate exhibits preclinical antitumor activity against the human glioma U87 xenograft. Proc Am Assoc Cancer Res, abstr 2326
16. Gamez I, Ryan R, and Keir S (2010) Corticorelin acetate exhibits preclinical antitumor activity, alone and with bevacizumab, against human brain tumor models. Proc Am Assoc Cancer Res, abstr 1557
17. Hsu JY, Wakelee HA (2009) Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 23(5):289-304
18. Kleinbaum DG, Klein M (2005) Survival analysis: a self-learning text, 2nd edn. Spring, Statistics for Biology and Health, New York
19. Zar JH (1999) Biostatistical analysis, 4th edn. Prentice-Hall, Upper Saddle River
20. Higgins B, Kolinsky K, Linn M, Adames V, Zhang YE, Moisa C, Dugan U, Heimbrook D, Packman K (2007) Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. Anticancer Res 27:2279-2287 (Pubitemid 47228065)
21. Yanagisawa M, Fujimoto-Ouchi K, Yorozu K, Yamashita Y, Mori K (2009) Antitumor activity of bevacizumab in combination with capecitabine and oxaliplatin in human colorectal cancer xenograft models. Oncol Rep 22:241-247
22. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
23. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95:1789-1797
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844 (Pubitemid 23132159)
25. Mordenti J, Thomsen K, Licko V, Chen H, Meng YG, Ferrara N (1999) Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans. Toxicol Pathol 27:14-21 (Pubitemid 29075738)
26. Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH (2008) Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol 126:953-958 (Pubitemid 352008378)
27. Hao Z, Huang Y, Cleman J, Jovin IS, Vale WW, Bale TL, Giordano FJ (2008) Urocortin 2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 105:3939-3944 (Pubitemid 351723503)
28. Tjuvajev J, Kolesnikov Y, Joshi R, Sherinski J, Koutcher L, Zhou Y, Matei C, Koutcher J, Kreek MJ, Blasberg R (1998) Antineoplastic properties of human corticotropin releasing factor: involvement of the nitric oxide pathway. In Vivo 12:1-10 (Pubitemid 28177273)
29. Investigator's Brochure Xerecept® (Corticorelin acetate): Version 1.0 Celtic Pharma Development Services Inc., New York
30. Schulte HM, Chrousos GP, Gold PW, Booth JD, Oldfield EH, Cutler GB Jr, Loriaux DL (1985) Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. J Clin Invest 75:1781-1785 (Pubitemid 15237785)